The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
Open accessAbstract
Summary: Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by increased total kidney volume (TKV) and renal failure. This study aimed to determine if height-adjusted TKV (htTKV) predicts the onset of renal insufficiency. Design, setting, participants, & measurements: This prospective, observational, longitudinal, multicenter study included 241 adults with ADPKD and preserved renal function. Magnetic resonance imaging and iothalamate clearance were used to measure htTKV and GFR, respectively. The association between baseline htTKV and the attainment of stage 3 CKD (GFR <60 ml/min per 1.73 m 2) during follow-up was determined. Results: After a mean follow-up of 7.9 years, stage 3 CKD was attained in 30.7% of the enrollees. Using baseline htTKV, negative correlations with GFR increased from −0.22 at baseline to −0.65 at year 8. In multivariable analysis, a baseline htTKV increase of 100 cc/m significantly predicted the development of CKD within 8 years with an odds ratio of 1.48 (95% confidence interval: 1.29, 1.70). In receiver operator characteristic curve analysis, baseline htTKV of 600 cc/m most accurately defined the risk of developing stage 3 CKD within 8 years with an area under the curve of 0.84 (95% confidence interval: 0.79, 0.90). htTKV was a better predictor than baseline age, serum creatinine, BUN, urinary albumin, or monocyte chemotactic protein-1 excretion (P<0.05). Conclusions: Baseline htTKV ≥600 cc/m predicted the risk of developing renal insufficiency in ADPKD patients at high risk for renal disease progression within 8 years of follow-up, qualifying htTKV as a prognostic biomarker in ADPKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationAutosomal Dominant Polycystic Kidney Disease
Gabow, P. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290508 · Cited by 974
Volume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Self-citationComparison of phenotypes of polycystic kidney disease types 1 and 2
Hateboer, N., v Dijk, M. A., Bogdanova, N., Coto, E., Saggar-Malik, A. K., Millan, J. L. S., Torra, R., Breuning, M., & Ravine, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03495-3 · Cited by 628
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Dalgaard, O. Z. (1957) · PubMed · Cited by 426
Chapman, A. B., Guay-Woodford, L. M., Grantham, J. J., Torres, V. E., Bae, K. T., Baumgarten, D. A., Kenney, P. J., King, B. F., Glockner, J. F., Wetzel, L. H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00185.x · Cited by 413
Self-citationLEVEY, A. S., GREENE, T., BECK, G. J., CAGGIULA, A. W., KUSEK, J. W., HUNSICKER, L. G., & KLAHR, S. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112426 · Cited by 399
Hogan, M. C., Masyuk, T. V., Page, L. J., Kubly, V. J., Bergstralh, E. J., Li, X., Kim, B., King, B. F., Glockner, J., Holmes, D. R., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121291 · Cited by 333
Self-citationGrantham, J. J., Chapman, A. B., & Torres, V. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00330705 · Cited by 278
Self-citationHarris, P. C., Bae, K. T., Rossetti, S., Torres, V. E., Grantham, J. J., Chapman, A. B., Guay-Woodford, L. M., King, B. F., Wetzel, L. H., Baumgarten, D. A., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080835 · Cited by 271
Self-citationKlahr, S., Breyer, J. A., Beck, G. J., Dennis, V. W., Hartman, J. A., Roth, D., Steinman, T. I., Wang, S. R., & Yamamoto, M. E. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v5122037 · Cited by 251
Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.
Chapman, A. B., Johnson, A. M., Gabow, P. A., & Schrier, R. W. (1994) · Journal of the American Society of Nephrology · doi:10.1681/asn.v561349 · Cited by 235
Self-citationRenal structure and hypertension in autosomal dominant polycystic kidney disease
Gabow, P. A., Chapman, A. B., Johnson, A. M., Tangel, D. J., Duley, I. T., Kaehny, W. D., Manco-Johnson, M., & Schrier, R. W. (1990) · Kidney International · doi:10.1038/ki.1990.330 · Cited by 225
Self-citationRossetti, S., Burton, S., Strmecki, L., Pond, G. R., San Millán, J. L., Zerres, K., Barratt, T. M., Ozen, S., Torres, V. E., Bergstralh, E. J., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000013300.11876.37 · Cited by 218
Self-citationAutosomal Dominant Polycystic Kidney Disease
Gabow, P. A. (1990) · The Cystic Kidney · doi:10.1007/978-94-009-0457-6_12 · Cited by 213
Johnson, A. M., & Gabow, P. A. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v8101560 · Cited by 202
BILATERAL POLYCYSTIC DISEASE OF THE KIDNEYS
DALGAARD, O. Z. (1959) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195904000-00016 · Cited by 181
Fick-Brosnahan, G. M., Belz, M. M., McFann, K. K., Johnson, A. M., & Schrier, R. W. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33379 · Cited by 178
A complete mutation screen of the ADPKD genes by DHPLC
Rossetti, S., Chauveau, D., Walker, D., Saggar-Malik, A., Winearls, C. G., Torres, V. E., & Harris, P. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00326.x · Cited by 170
Self-citationSirolimus Therapy to Halt the Progression of ADPKD
Perico, N., Antiga, L., Caroli, A., Ruggenenti, P., Fasolini, G., Cafaro, M., Ondei, P., Rubis, N., Diadei, O., Gherardi, G., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121302 · Cited by 165
Earle, D. P. (1958) · Archives of Internal Medicine · doi:10.1001/archinte.1958.00260200160014 · Cited by 154
The HALT Polycystic Kidney Disease Trials: Design and Implementation
Chapman, A. B., Torres, V. E., Perrone, R. D., Steinman, T. I., Bae, K. T., Miller, J. P., Miskulin, D. C., Rahbari-Oskoui, F. F., Masoumi, A., Hogan, M. C., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04310709 · Cited by 152
Self-citationKistler, A. D., Poster, D., Krauer, F., Weishaupt, D., Raina, S., Senn, O., Binet, I., Spanaus, K. S., Wuthrich, R. P., & Serra, A. L. (2008) · Kidney International · doi:10.1038/ki.2008.558 · Cited by 149
Zheng, D., Wolfe, M., Cowley, B. D., Wallace, D. P., Yamaguchi, T., & Grantham, J. J. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088720.61783.19 · Cited by 138
Self-citationKing, B. F., Reed, J. E., Bergstralh, E. J., Sheedy, P. F., & Torres, V. E. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1181505 · Cited by 125
Self-citationGretz, N., Zeier, M., Geberth, S. K., Strauch, M., & Ritz, E. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80068-x · Cited by 110
Determinants of renal volume in autosomal-dominant polycystic kidney disease
Grantham, J. J., Cook, L. T., Torres, V. E., Bost, J. E., Chapman, A. B., Harris, P. C., Guay‐Woodford, L. M., & Bae, K. T. (2007) · Kidney International · doi:10.1038/sj.ki.5002624 · Cited by 108
Self-citationImaging for the prognosis of autosomal dominant polycystic kidney disease
Bae, K. T., & Grantham, J. J. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.214 · Cited by 92
Self-citationmTOR Inhibitors in Polycystic Kidney Disease
Watnick, T. J., & Germino, G. G. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006925 · Cited by 87
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients not yet on Dialysis
Rizk, D. V., Jurkovitz, C. T., Veledar, E., Bagby, S. P., Baumgarten, D. A., Rahbari-Oskoui, F. F., Steinman, T. I., & Chapman, A. B. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02410508 · Cited by 84
Self-citationIncident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease
Dicks, E. L., Ravani, P., Langman, D., Davidson, W. S., Pei, Y., & Parfrey, P. S. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01581105 · Cited by 80
Sise, C. B., Kusaka, M., Wetzel, L. H., Winklhofer, F. T., Cowley, B. D., Cook, L. T., Gordon, M. A., & Grantham, J. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00433.x · Cited by 78
Self-citationPatients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease
Wong, H., Vivian, L., Weiler, G., & Filler, G. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.12.026 · Cited by 68
Antiga, L., Piccinelli, M., Fasolini, G., Ene‐Iordache, B., Ondei, P., Bruno, S., Remuzzi, G., & Remuzzi, A. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02251205 · Cited by 41
Cited by
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Chapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citation
Metadata
- Authors
- Chapman, A. B., Bost, J. E., Torres, V. E., Guay-Woodford, L., Bae, K. T., Landsittel, D., Li, J., King, B. F., Martin, D., Wetzel, L. H., Lockhart, M. E., Harris, P. C., Moxey-Mims, M., Flessner, M., Bennett, W. M., & Grantham, J. J.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2012-03
- Volume
- 7
- Issue
- 3
- Pages
- 479-486
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2143990369
- Cited by
- 378
- References
- 36
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.